EPAS1 and von Hippel-Lindau disease: Jonasch et al. performed a Phase 2, open-label, single-group trial of 61 patients with RCC associated with VHL disease with measurable, localized RCCs of <3 cm; the researchers investigated the efficacy and safety of HIF-2α inhibitor belzutifan (NCT03401788) administered orally at a dose of 120 mg daily (50).